2003/013

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

REQUEST **CONTINUED EXAMINATION (RCE)**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to	o a collection of information unle	ess it displays a valid OMB control number
REQUEST	Application Number	10/632,003
FOR	Filing Date	July 30, 2003
INUED EXAMINATION (RCE)	First Named Inventor	Watson, et al.
TRANSMITTAL	Group Art Unit	2421
Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, ovides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	Examiner Name	Montoya, Oschta
	Attorney Docket Number	0260256

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114			
a. Previously submitted			
i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on			
ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on			
iii. Other			
b. X Enclosed			
i. Amendment and Response to Final Office Action			
ii. Affidavit(s)/Declaration(s)			
iii. Information Disclosure Statement (IDS)			
iv. Other			
2. Miscellaneous			
a. Suspension of action on the above-identified application is requested under 37 C.F.R.§ 1.103(c) for			
a period of months. (Period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17(i) required) b. Other			
3. Fees The RCE (see under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.			
a. X The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-0731			
i. X RCE fee required under 37 C.F.R. § 1.17(e)			
ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)			
i <u>ii.</u> Other <u>Additional Claims Fee</u>			
b Check in the amount of \$ enclosed			
c. X Payment by credit card in the amount of \$ 810 (Form PTO- 2038 enclosed)			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (Print/Type) Farshard Farjami, Esq.	Registration No. (Attorney/Agent) 41,014		
Signature	Date 2/15/10		
CERTIFICATE OF MAILING OR TRANSMISSION			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:			
Name (Print/Type) / 1 Jembier Darra	05 11		
Signature Constitut Mules Date 2/15/10			
Burden Hour Statement: This farm is estimated to take 0.2 hours to complete. Time will vary dep	anding upon the needs of the individual case. Any comments on the		

Durven mour Statement: This term is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.